Clinical trial · Observational
Investigation of Cisplatin-Related Kidney Toxicity
Investigation of Germline Genetic Determinants and Early Biomarkers of Cisplatin-Related Nephrotoxicity
NCT00984035CI-TRIAL-00034795completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify novel biomarkers of kidney injury in patients receiving cisplatin. This study will also collect DNA for future analysis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample (DNA) | Other | — | UNRESOLVED |
| blood samples (biomarkers) | Other | — | UNRESOLVED |
| urine samples (biomarkers) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Prospecitive Analysis
- description
- Patients currently receiving cisplatin as treatment for their cancer.
- interventionNames
- Other: urine samples (biomarkers)
- Other: blood samples (biomarkers)
- Other: blood sample (DNA)
- label
- Restrospective Analysis
- description
- Patients that have previously received cisplatin as treatment for their cancer.
- interventionNames
- Other: blood sample (DNA)
Primary outcomes (1)
- measure
- Change in urine biomarker (NGAL) after cisplatin
- timeFrame
- while on drug and up to 35 days after end of treatment
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Prospective Analysis Group Inclusion Criteria: * Patients about to receive intravenous cisplatin for the first time as part of cancer chemotherapy. * Aged 18 years and older. * Ability to understand and willingness to sign a written consent document. * Patients may be receiving cisplatin in combination with other chemotherapeutic agents. * Patients may be receiving cisplatin in the context of another clinical trial. Exclusion Criteria: * Prior receipt of cisplatin. * Patients on dialysis or other renal replacement therapy prior to starting cisplatin. * Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid replacement medication are eligible). Retrospective Analysis Group Inclusion Criteria: * Patients that have previously received intravenous cisplatin as part of cancer chemotherapy. * Aged 18 years and older. * Ability to understand and willingness to sign a written consent document. * Patients that received cisplatin in combination with other chemotherapeutic agents are eligible. * Patients that received cisplatin in the context of a clinical trial are eligible. Exclusion Criteria: * Unable or unwilling to submit to a one-time blood draw.
References
Publications (0)
Data not yet available
No reference posted for this study.